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Introduction of leukocytosis and decreasing levels of c-reactive
protein. In Patients 1 and 2 thrombolytic therapy led
Immediate treatment of acute portal and mesenteric to the complete recanalisation of the thrombosed veins
within 8 days of thrombolysis (Figs 1 and 2) so thatvein thrombosis is necessary because of the risk of
bowel infarction. Recanalisation of the venous drain- the catheter could be removed. In Patient 3 the treat-
ment had to be discontinued on day 5 due to bleedingage system by transarterial thrombolysis leads to im-
proved venous outflow in the involved bowel from the puncture site in the right groin. At this point
the portal vein was completely recanalised while thesegments and may prevent the risk of haemorrhagic
bowel ischaemia. superior mesenteric vein remained thrombosed. All
three patients were kept on intravenous heparin until
coumarin therapy for long-time prevention of throm-
botic re-occurrence could be started.
Case Report
Three men, aged between 35 and 61, were admitted
Discussionto our hospital with acute onset of abdominal pain
and bloody diarrhoea. Colour Doppler ultrasound and
Patients with acute portal and mesenteric vein throm-CT scans of the abdomen revealed thrombosis of the
bosis are at high risk of developing haemorrhagicportal and superior mesenteric veins in all three
bowel infarction due to venous outflow obstruction.patients. A Protein C deficiency could be verified in
Different therapeutic options with the aim of the re-one of the patients but in the other two no predisposing
canalisation of the bowel’s venous system have beenfactors were present.
described. Thrombectomy and thrombolytic treatment,A 5 F Cordis catheter (Side Winder SIM 2, Johnson &
either percutaneously through a transhepatic catheter1Johnson) was inserted into the right common femoral
or via a transjugular intrahepatic portosystemic shuntartery and advanced into the superior mesenteric ar-
(TIPS),2 are highly invasive methods. Furthermore,tery for thrombolysis with urokinase at a concentration
they bear a considerable risk of incomplete re-of 100 000 IU/h. The patients were heparinised sim-
canalisation as neither thrombectomy nor retrogradeultaneously to prevent reocclusion. Clinical symptoms
infusion of the thrombolytic agent reaches the distal,improved dramatically in all three patients within 48 h
intramural veins and venules of the bowel.of treatment. Abdominal pain and bloody diarrhoea
Apart from the lower invasiveness of the trans-diminished and laboratory tests showed improvement
arterial approach, the recanalisation of the whole
venous system including the small intramural vessels
∗ Please address all correspondence to: G. Antoch, MD, Chirurgische becomes possible due to the antegrade infusion of theAbteilung, Marien-Hospital Duesseldorf, Rochusstrasse 2, 40479
Duesseldorf, Germany. lytic agent via the arterial circulation. In all three of
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our patients, clinical symptoms diminished within 2
days and the patients were discharged from hospital
3 to 4 weeks later, symptom-free. In Patient 3 throm-
bolytic treatment had to be discontinued on day 5 due
to bleeding from the catheter insertion site in the right
groin. At this point the portal vein had recanalised,
but the occlusion of the SMV persisted. The fact that
he remained asymptomatic may be explained by the
development of sufficient collaterals during throm-
bolysis. None of our patients developed major com-
plications such as acute intestinal bleeding or catheter
dislocation, but we believe that such patients should be
monitored on the ICU until the treatment is terminated.
To our knowledge only three cases of portal and
mesenteric vein thrombosis treated with transarterial
thrombolysis have been described previously. In all
these patients treatment was successful.3–5
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thrombolytic therapy: the portal vein has completely recanalised
(⇓) after 8 days of thrombolysis.
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